Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

Response to PXT3003 on efficacy outcomes (Full Analysis Set, n = 80). Data are mean (s.d.) baseline and final values, and % (s.d.) of improvement for each treatment group and PLI. Differences between treatment groups were assessed by Analysis of Covariance (Ancova) on log-transformed values by adjus...

Full description

Bibliographic Details
Main Authors: Attarian, Shahram, Jean-Michel Vallat, Magy, Laurent, Funalot, Benoît, Pierre-Marie Gonnaud, Lacour, Arnaud, Péréon, Yann, Dubourg, Odile, Pouget, Jean, Micallef, Joëlle, Franques, Jérôme, Marie-Noëlle Lefebvre, Ghorab, Karima, Al-Moussawi, Mahmoud, Tiffreau, Vincent, Preudhomme, Marguerite, Magot, Armelle, Leclair-Visonneau, Laurène, Stojkovic, Tanya, Bossi, Laura, Lehert, Philippe, Gilbert, Walter, Bertrand, Viviane, Mandel, Jonas, Milet, Aude, Hajj, Rodolphe, Boudiaf, Lamia, Scart-Grès, Catherine, Nabirotchkin, Serguei, Guedj, Mickael, Chumakov, Ilya, Cohen, Daniel
Format: Text
Language:unknown
Published: figshare 2019
Subjects:
Biochemistry
Medicine
Neuroscience
Pharmacology
Biotechnology
39999 Chemical Sciences not elsewhere classified
FOS Chemical sciences
Science Policy
Charcot
DML
Online Access:https://dx.doi.org/10.6084/m9.figshare.10037333.v1
https://springernature.figshare.com/articles/Additional_file_4_Table_S4_of_Erratum_to_An_exploratory_randomised_double-blind_and_placebo-controlled_phase_2_study_of_a_combination_of_baclofen_naltrexone_and_sorbitol_PXT3003_in_patients_with_Charcot-Marie-Tooth_disease_type_1A/10037333/1
Description
Summary:Response to PXT3003 on efficacy outcomes (Full Analysis Set, n = 80). Data are mean (s.d.) baseline and final values, and % (s.d.) of improvement for each treatment group and PLI. Differences between treatment groups were assessed by Analysis of Covariance (Ancova) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90 % CI). Dose-effect was tested through Spearman’s rank correlation. P-values are one-tailed. CMTNS = Charcot-Marie-Tooth Neuropathy Score; ONLS = Overall Neuropathy Limitations Scale; 6MWT = 6-Minute Walk Test; 9HPT = 9-Hole Peg Test; CMAP = Amplitudes of Compound Muscle Action Potentials; MCV = Motor Conduction Velocity; DML = Distal Motor Latency; SNAP = Amplitudes of Sensory Nerve Action Potentials; SCV = Sensitive Conduction Velocity; VAS = Visual Analog Scale; CGI = Clinical Global Impression. (DOC 168 kb)

Similar Items